Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Williams VC
and increases Caspase-3 and cleaved-PARP levels in SK-MEL-2 and MeWo cells
2012 Sep-Oct
4-triazol-1-yl)-1H-pyrrolo[2
It has minimal inhibition of UCHL-1
SU14813 maleate - CAS# 849643-15-8 Size:Solid 10 mg Williams VCSU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet derived growth factor receptors (PDGFR), KIT, and fms like tyrosine kinase 3 (FLT 3) (1). SU14813 was developed as a next generation TKI agent following sunitinib (SU11248) designed to demonstrate optimized pharmacokinetic (PK) and tolerability profiles. SU14813 demonstrated broad and potent antitumor activity
US$ 51.00
US$ 74.75
US$ 14.20
US$ 15.90
US$ 31.85